---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-018358"
form_type: "8-K"
ticker: "WVE"
cik: "0001631574"
company_name: "Wave Life Sciences Ltd."
filed_at: "2023-01-30T23:59:59+00:00"
generated_at: "2026-06-20T06:37:55.229436+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Wave closes $50M equity sale to GSK affiliate; collaboration effective, triggering $120M upfront

## Summary
- Closed sale of 10,683,761 ordinary shares to Glaxo Group Limited for $50M cash.
- Collaboration and License Agreement with GSK effective January 27, 2023.
- GSK must now pay $120M upfront cash plus first research support funding.
- Investor Agreement with GGL entered into as previously disclosed on Dec 13, 2022.

## SEC filing metadata
- accession: 0001193125-23-018358
- form_type: 8-K
- ticker: WVE
- cik: 0001631574
- company_name: Wave Life Sciences Ltd.
- filed_at: 2023-01-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1631574/000119312523018358/0001193125-23-018358-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1631574/000119312523018358/d451816d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-018358
- JSON: https://secwatch.observer/filing/0001193125-23-018358.json
- Plain text: https://secwatch.observer/filing/0001193125-23-018358.txt

## Key facts
- Material Agreements
  Wave Life Sciences Ltd. entered into Investor Agreement with Glaxo Group Limited (effective 2023-01-26).
  - Action: entry
  - Counterparty: Glaxo Group Limited
  - Effective: 2023-01-26
  source text: On January 26, 2023, as a condition to and simultaneous with the closing of the equity issuance contemplated by the Share Purchase Agreement (the “Share Purchase Agreement”), dated December 13, 2022, by and between Wave Life Sciences Ltd. (including its subsidiaries, the “Company” or “Wave”) and Glaxo Group Limited (“GGL”), the Company entered into an Investor Agreement with GGL (the “Investor Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1631574/000119312523018358/0001193125-23-018358-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.